Jan. 21 at 4:02 PM
$ALVO I'm adding this to my core positions at
$5 entry. Multiple approved biosimilars, not generics, with real partners and manufacturing scale. Commercial execution is proven, and current pricing reflects skepticism. But they're going after cheaper equivalents of drugs already in use. That's always in style. With the right execution and partnerships, we can beat the risks of unreliable manufacturing, regulatory approvals, pricing pressure, and competition.
